

Sub D  
a

1. (once amended) A composition for enteral administration comprising at least one anti-HIV drug and at least one cortisol blocker selected from the group consisting of procaine HCl, zinc, zinc salts, zinc heptahydrate, lidocaine HCl, phosphatidylserine, RU-486, HMB, pregnenalone, clonidine and ipriflavone.
2. (once amended) The composition according to claim 1 wherein said anti-HIV drug is selected from the group consisting of [AZT,] DDC, DDI, D<sub>4</sub>T, 3TC, saquinavir, ritonavir, indinavir, nelfinavir, nevirapine, delevirdine, abacarvir, efavirenz, adefavir, [BBH-10652, FTC-TBD, NKC-482/TBD, PMPA/Dis-POCPMPA] BCH 10652, FTC, MKC-442, and Bis-POC-PMPA.

a

6. (once amended) A method for the management of side effects associated with the administration of anti-HIV drug therapy, said method comprising the enteral administration to a patient undergoing anti-HIV drug therapy a therapeutically effective amount of a least one cortisol blocker selected from the group consisting of procaine HCl, zinc, zinc salts, zinc heptahydrate, lidocaine HCl, phosphatidylserine, RU- 486, HMB, pregnenalone, clonidine and ipriflavone.
7. (once amended) The method according to claim 6 wherein said anti-HIV drug is selected from the group consisting of [AZT,] DDC, DDI, D<sub>4</sub>T, 3TC, saquinavir, ritonavir, indinavir, nelfinavir, nevirapine, delevirdine, abacarvir, efavirenz, adefavir, [BBH-10652, FTC-TBD, NKC-482/TBD, PMPA/Dis-POCPMPA] BCH 10652, FTC, MKC-442 and Bis-POC-PMPA.

Sub C2  
a1  
10. (once amended) A method for the treatment for human immunodeficiency virus infected patients, said method comprising enterally administering to said patient at least one anti-HIV drug and at least one cortisol blocker selected from the group consisting of procaine HCl, zinc, zinc salts, zinc heptahydrate, lidocaine HCl, phosphatidylserine, HMB, RU-486, pregnenolone, clonidine and ipriflavone, at levels effective to protect the patient from at least one undesirable side effect of the anti-HIV drug selected from the group consisting of bone marrow suppression, nausea, myalgia, insomnia, Cushings like syndrome, anemia, disruption of metabolism, elevated triglycerides, elevated cholesterol, insulin intolerance, buffalo humps and protease paunches.

11. (once amended) The method according to claim 10 wherein said anti-HIV drug is selected from the group consisting of [AZT,] DDC, DDI, D<sub>4</sub>T, 3TC, saquinavir, ritonavir, indinavir, nelfinavir, nevirapine, delevirdine, abacavir, efavirenz, adefavir, [BBH-10652, FTC-TBD, NKC-482/TBD, PMPA/Dis-POCPMPA] BCH 10652, FTC, MKC 442 and Bis-POC-PMPA.

a8  
15. (once amended) A method to treat the catabolic effects associated with human immunodeficiency virus in a human, said method comprising the enteral administration to said human, of a therapeutically effective amount of at least one cortisol blocker selected from the group consisting of procaine HCl, zinc, zinc salts,

218  
cancel

~~zinc heptahydrate, lidocaine HCl, phosphatidylserine, RU-486, HMB, pregnenalone,  
clonidine and ipriflavone.~~

17. (once amended) The composition according to claim 1 wherein said cortisol blocker  
comprises procaine HCl, zinc heptahydrate and ascorbic acid.

18. (once amended) The method according to claim 6 wherein said cortisol blocker  
comprises procaine HCl, zinc heptahydrate and ascorbic acid.

19. (once amended) The method according to claim 10 wherein said cortisol blocker  
comprises procaine HCl, zinc heptahydrate and ascorbic acid.

20. (once amended) The method according to claim 15 wherein said cortisol blocker  
comprises procaine HCl, zinc heptahydrate and ascorbic acid.

✓ / / / /  
Please cancel Claims 4, 8, 12 and 16.

#### REMARKS

Minor corrections have been made to the specification. The minor corrections add no new matter. More specific descriptions for the four drugs under development are given. The information came from File ADISALERTS on the STN search system. Claims 1, 2, 6, 7, 10, 11, 15 and 17-20 have been amended and Claims 4, 8, 12 and 16 have been cancelled. The Examiner has referred to a reference called Lemay et al., Int. Conf. AIDS, vol.5, 1989. The Applicant can find no reference with Lemay as the author or editor but has made the assumption